NASDAQ · BNR
Burning Rock Biotech Limited
Healthcare · Medical - Diagnostics & Research
$11.99
Down-$0.37 (-3.09%)
Updated Sep 10, 2026, 10:24 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 18.36M
- P/E ratio
- -1.05
- Dividend yield
- 0.00%
- 52-week range
- $6.79 – $23.75
- Volume
- 44.86K
- Avg. volume
- 39.18K
Price performance
BNR price history
1M range · 20 trading sessions · Daily adjusted prices
BNR closed at $11.99 after 20 trading sessions, up 20.75% for the selected period.
- Last close
- $11.99
- Period change
- +20.75%
- Period low
- $8.83
- Period high
- $11.99
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $11.09 | $13.26 | $10.85 | $11.99 | 44.86K |
| Sep 8, 2026 | $11.17 | $12.46 | $10.61 | $10.71 | 244.64K |
| Sep 4, 2026 | $10.16 | $12.05 | $10.16 | $11.99 | 97.76K |
| Sep 3, 2026 | $9.56 | $10.80 | $9.28 | $10.78 | 134.04K |
| Sep 2, 2026 | $9.45 | $9.48 | $9.15 | $9.15 | 3.62K |
| Sep 1, 2026 | $9.33 | $9.68 | $9.22 | $9.22 | 3.4K |
| Aug 31, 2026 | $9.56 | $9.79 | $9.40 | $9.45 | 5.7K |
| Aug 28, 2026 | $9.79 | $10.30 | $9.79 | $10.19 | 29.18K |
| Aug 27, 2026 | $9.26 | $10.00 | $9.26 | $10.00 | 6.34K |
| Aug 26, 2026 | $9.26 | $10.49 | $9.26 | $10.44 | 3.57K |
| Aug 25, 2026 | $10.32 | $10.898 | $9.108 | $9.80 | 12.84K |
| Aug 24, 2026 | $10.32 | $10.32 | $10.32 | $10.32 | 1.51K |
| Aug 21, 2026 | $9.40 | $10.25 | $9.11 | $9.78 | 4.63K |
| Aug 20, 2026 | $10.0246 | $10.89 | $9.25 | $9.25 | 3.47K |
| Aug 19, 2026 | $9.77 | $10.0548 | $9.77 | $9.79 | 1.4K |
| Aug 18, 2026 | $9.35 | $10.00 | $9.31 | $9.31 | 11.83K |
| Aug 17, 2026 | $9.18 | $9.18 | $8.88 | $9.10 | 3.57K |
| Aug 14, 2026 | $9.34 | $9.81 | $8.83 | $8.83 | 16.1K |
| Aug 13, 2026 | $9.83 | $9.83 | $9.29 | $9.29 | 2.97K |
| Aug 12, 2026 | $10.20 | $10.20 | $9.93 | $9.93 | 1.11K |
Latest BNR news
The latest Smart Investors Daily articles mentioning BNR.
Stock researchResearch & News · Analysis
Loading stock research…
